Gabapentin Market Size, Share & Trends Analysis Report By Product Type (Tablets, Capsule), Application (Epilepsy, Neuropathic Pain), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2022 To 2030

Gabapentin belongs to class of anticonvulsants. The medication is prescribed for the control of seizures in the treatment of epilepsy. According to WHO, nearly 5 million individuals worldwide suffer from epilepsy, a persistent brain disorder. Epilepsy is one of the most common neurological disorders, which is characterized by recurring seizures, which are brief bursts of uncontrollable movement that can affect either a small portion of the body (partial) or the entire body (generalized). They can also occasionally be followed by loss of control and consciousness over bowel or bladder function.

The rise in geriatric population, increasing investments in R&D by pharmaceutical companies, rise in government efforts, ease of purchase, and rising product approvals are all factors that are expected to fuel market growth. Moreover, increasing awareness, for instance, November is celebrated as National Epilepsy Awareness Month (NEAM) which helps in spreading awareness and taking up steps and initiatives to understand and help control the condition further propelling the growth of the market. However, it is anticipated that the lack of health reimbursement policies, high cost and side effects associated with gabapentin, and rigorous regulatory policies is expected to restrain the market growth.

Gabapentin was originally developed and prescribed for the treatment of epilepsy and seizures. However, in recent years, the prescription has increased 5-fold owing to a growing number of doctors prescribing gabapentin "off-label" for both acute and chronic pain. Some are even prescribing it in place of opioids, while others prescribe it along with opioids.

North America dominated the overall market in 2022 which can be attributed to the growing population being diagnosed with central nervous system disorders that further causes seizures. It is seen that around 1 in every 26 people in U.S. are diagnosed with epilepsy. Moreover, the region shows a high incidence of geriatric population that is more prone to CNS disorder. It is estimated that the incidence of epilepsy is around 85 per 100,000 for people who are aged 65-69 years and the incidence rate rises with increasing age of an individual owing to associated risk factors for epilepsy being more common in older adults.

Gabapentin Market Segmentation

Major companies operating in the market include Glenmark Pharmaceuticals Limited, Sun Pharmaceutical Industries Ltd., Apotex Inc., GSK plc, Alkem Labs, and Jiangsu Nhwa Pharmaceutical Co., Ltd. These players are focusing on product launches and geographical expansion to maintain their presence in the market. For instance, in December 2020, Glenmark Pharmaceuticals Limited received ANDA approval for Gabapentin Enacarbil Extended-Release Tablets.